OPKO Health’s Acquisition of ModeX Therapeutics

Goodwin advised ModeX Therapeutics, Inc. on the deal.

ModeX Therapeutics, Inc. announced its sale to OPKO Health, Inc. (NASDAQ: OPK) for $300 million in OPKO common stock.

ModeX Therapeutics is a biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. The company has developed highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, simpler manufacturing and potentially better specificity and safety.

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies.

The Goodwin team was led by Stuart Cable (Picture) and Ed Amer, and included Sam Beavers, Monique Noel, Tom Maher, and Daisy Figueroa (corporate); Sarah Bock (ERISA & Executive Compensation); Dan Karelitz (Tax); Tim Holahan (Employment); Kara Kuritz (Antitrust); and Chris Denn (Life Sciences).

Involved fees earner: Edward Amer – Goodwin Procter; Samuel Beavers – Goodwin Procter; Sarah Bock – Goodwin Procter; Stuart Cable – Goodwin Procter; Christopher Denn – Goodwin Procter; Timothy Holahan – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Kara Kuritz – Goodwin Procter; Monique Noel – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: ModeX Therapeutics, Inc.;

Martina Bellini

Author: Martina Bellini